| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg | |||
| 100mg | |||
| 500mg | |||
| 1g | |||
| Other Sizes |
| Targets |
WAY-348941 targets the D1 domain of CD4, a co-receptor on T cells that plays a critical role in T-cell activation and immune responses. By binding to the CD4 D1 domain, WAY-348941 modulates CD4-mediated immune signaling. It is also referred to as FGF22-IN-1 (compound c1) and is a potent CD4 D1 inhibitor.
|
|---|---|
| ln Vitro |
In vitro, WAY-348941 is a small-molecule inhibitor targeting the D1 domain of CD4. In cell-based models, it suppresses T-cell activation and blunts cytokine production in response to stimuli, indicating functional inhibition of CD4-mediated immune signaling. These in vitro properties make WAY-348941 a valuable tool for studying CD4-mediated immune responses and T-cell activation.
|
| ln Vivo |
In vivo, WAY-348941 shows immunomodulatory effects in preclinical assays. As a CD4 D1 inhibitor that suppresses T-cell activation, it may have potential for treating autoimmune diseases or other conditions involving aberrant T-cell activation. However, detailed in vivo efficacy data are limited in publicly available sources.
|
| Enzyme Assay |
The in vitro receptor binding assay for WAY-348941 involves measuring its binding to the CD4 D1 domain. The compound is incubated with recombinant CD4 protein or CD4-expressing cells in the presence of a labeled CD4 ligand or antibody. Binding affinity is determined using surface plasmon resonance, ELISA, or flow cytometry-based binding assays. Functional inhibition of CD4-mediated signaling can be assessed by measuring T-cell activation markers or cytokine production.
|
| Cell Assay |
The in vitro cell-based assay for WAY-348941 involves culturing T cells and treating them with the compound to assess effects on T-cell activation. Cells are stimulated with anti-CD3/anti-CD28 antibodies or antigen-presenting cells in the presence or absence of WAY-348941 at various concentrations. T-cell activation is assessed by measuring CD25 or CD69 expression by flow cytometry, cytokine production (e.g., IL-2, IFN-γ) by ELISA, and proliferation by CFSE dilution or [3H]-thymidine incorporation. Cell viability is assessed using MTT or CellTiter-Glo assays.
|
| Animal Protocol |
In vivo animal studies for WAY-348941 have not been extensively reported. If conducted, such studies might involve mouse models of autoimmune diseases or transplantation, where WAY-348941 is administered and immune responses are assessed. Standard protocols for immunomodulatory compound evaluation would be employed. No specific data are available from publicly accessible sources.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of WAY-348941 have not been extensively characterized. As a small molecule with a molecular weight of 269.32 and a molecular formula of C14H11N3OS, it is expected to have moderate oral bioavailability. The compound can be formulated for in vivo administration. Detailed PK parameters such as half-life, Cmax, and bioavailability are not available from publicly accessible sources.
|
| Toxicity/Toxicokinetics |
The toxicity profile of WAY-348941 has not been systematically evaluated. As a CD4 D1 inhibitor that modulates T-cell activation, its primary safety concerns would relate to immunosuppression and increased susceptibility to infections. Standard toxicology assessments would include acute and sub-chronic toxicity studies in rodents, with endpoints including clinical signs, body weight, clinical pathology, and histopathology. No specific toxicity data are available.
|
| References | |
| Additional Infomation |
WAY-348941 is a research compound and has not been approved for clinical use. It is a small-molecule inhibitor targeting the D1 domain of CD4, showing immunomodulatory effects in preclinical assays. In cell-based models, it suppresses T-cell activation and blunts cytokine production in response to stimuli, indicating functional inhibition of CD4-mediated immune signaling. WAY-348941 is also known as FGF22-IN-1 (compound c1) and is a potent CD4 D1 inhibitor.
|
| Molecular Formula |
C14H11N3OS
|
|---|---|
| Molecular Weight |
269.322
|
| Exact Mass |
269.062
|
| Elemental Analysis |
C, 62.44; H, 4.12; N, 15.60; O, 5.94; S, 11.90
|
| CAS # |
113143-13-8
|
| PubChem CID |
135520251
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Index of Refraction |
1.707
|
| LogP |
2.39
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
19
|
| Complexity |
361
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C2C(=C1)C(=CN2)/C=N/NC(=O)C3=CC=CS3
|
| InChi Key |
O=C(C1=CC=CS1)N/N=C/C2=CNC3=C2C=CC=C3
|
| InChi Code |
InChI=1S/C14H11N3OS/c18-14(13-6-3-7-19-13)17-16-9-10-8-15-12-5-2-1-4-11(10)12/h1-9,15H,(H,17,18)/b16-9+
|
| Chemical Name |
2-Thiophenecarboxylic acid, 2-(1H-indol-3-ylmethylene)hydrazide
|
| Synonyms |
WAY-348941; WAY 348941; WAY348941;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~371.31 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.28 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7131 mL | 18.5653 mL | 37.1306 mL | |
| 5 mM | 0.7426 mL | 3.7131 mL | 7.4261 mL | |
| 10 mM | 0.3713 mL | 1.8565 mL | 3.7131 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
